Your browser doesn't support javascript.
loading
CI-924 effects on plasma lipids in patients with type II and type IV hyperlipoproteinaemia.
Corder, C N; Kloer, H U; Price, M D.
Afiliación
  • Corder CN; Clinical Pharmacology Program, Oklahoma Medical Research Foundation, Oklahoma City.
Eur J Clin Pharmacol ; 37(5): 477-81, 1989.
Article en En | MEDLINE | ID: mdl-2598985
ABSTRACT
CI-924 (CI), 5,5'-[[1,1'-biphenyl]-2,5-diylbis(oxy)]bis[2,2- dimethylpentanoic acid] is chemically similar to gemfibrozil. Patients with Type II (n = 13) and Type IV (n = 22) hyperlipoproteinaemia (HLP) were maintained 12 weeks on a baseline diet containing 55% sugar, 15% protein 30% fat and less than 300 mg cholesterol daily to stabilize weight and lipids. They were then entered in a parallel group double-blinded protocol and received 0, 300, 600, or 1200 mg CI p.o. daily for 12 weeks. CI consistently elevated anti-atherogenic HDL and lowered VLDL at 600 mg/day in both Type II and Type IV HPL at 8 weeks. In Type II patients, CI lowered cholesterol, decreased LDL/HDL and increased ApoA-I. In Type IV patients, CI also lowered TC while elevating LDL and ApoA-II. CI had no effect on Apo-B, LDL-ApoB, or Apo-E.
Asunto(s)
Buscar en Google
Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Gemfibrozilo / Hiperlipoproteinemia Tipo II / Hiperlipoproteinemia Tipo IV / Lípidos / Hipolipemiantes Tipo de estudio: Clinical_trials Límite: Humans / Male / Middle aged Idioma: En Revista: Eur J Clin Pharmacol Año: 1989 Tipo del documento: Article
Buscar en Google
Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Gemfibrozilo / Hiperlipoproteinemia Tipo II / Hiperlipoproteinemia Tipo IV / Lípidos / Hipolipemiantes Tipo de estudio: Clinical_trials Límite: Humans / Male / Middle aged Idioma: En Revista: Eur J Clin Pharmacol Año: 1989 Tipo del documento: Article
...